PBM
Psyence Biomedical Ltd. (NASDAQ)
Healthcare — Biotechnology
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
None
$3.11
+$0.05 (+1.63%)
Sign in to add PBM to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $11.86M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-12.56 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -58.62% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 44.7 |
| Beta | 1.65 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $468.36 |
| 52-Week Low | $1.92 |
| 50-Day Avg | $4.68 |
| 200-Day Avg | $42.45 |
| Avg Volume | $2.66M |
| Volume | 40.0K |
Performance Analysis
NEUTRALPBM presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($1.92), which could present a value opportunity.
~
RSI at 44.7 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:25 UTC
Back to Screener Export Report